



उ०प्र० आयुर्विज्ञान विश्वविद्यालय

सैफई, इटावा (उ०प्र०) – 206 130

Uttar Pradesh University of Medical Sciences

Saifai, Etawah (U.P.)– 206 130

No. 3855 /IEC (1469-CD)/UPUMS/2024-25

Date: 15 / 02 /2025

Office Order

Uttar Pradesh University of Medical Sciences has received Six new proposals for the Execution of the new clinical trials through its CRO/ SMO. The following faculty members of the University are hereby nominated as PI/ Co-PI for the successful implementation of the below mentioned Clinical Trials:

Sl No.	Name of the Clinical Trial	Department	Principal Investigator	Co-Principal Investigator
1	A multicenter, randomized, double-blind, active-control phase III clinical trial of WOXheal® [Diperoxochloric acid] topical solution in the treatment of pressure ulcers – in comparison with the active-control 0.9% sodium chloride topical solution in addition to standard of care	General Surgery	Prof. (Dr.) Shailendra Pal Singh	1. Dr. Gaurav Mishra 2. Dr. Vinay Kanaujia
2	An open label, single-dose, multi-center, randomized, balanced, two-treatment, two-sequence four-period, fully-replicated, pharmacokinetic bioequivalence study of American Regent, Inc. test formulation of Leuprolide acetate for depot suspension (7.5 mg 1-month or 4-weeks) and Lupron Depot (leuprolide acetate for depot suspension) 7.5 mg for 1-month (4-weeks) of AbbVie Inc. North Chicago, IL 60064 administered as an intramuscular injection in adult male prostatic carcinoma patients undergoing initial therapy or receiving a stable regimen of leuprolide acetate for depot suspension via intramuscular injection route	Urology	Dr. Mubashir Ali Khan	Dr. Ankit Sachan Dr. Namita
3	Multicentre prospective & retrospective remnant Biospecimen collection program for study and future biomedical research	Gynaecology	Dr. Kalpana Kumari	Dr. Savita Agarwal (Pathology Dept.)
4	A Randomized, Double-Blind, Multicenter, Two-Period, Two-Treatment, Two-Sequence, Crossover, Multiple-Dose, Steady State Bioequivalence Study of Olaparib Tablets 150 mg (2*150 mg tablets) of Zydus Lifesciences Limited with PrLYNPARZA® Olaparib Tablets 150 mg (2*150 mg tablets) of AstraZeneca Canada Inc., in Adult Patients with Cancer and Stable on Olaparib Therapy under Fasting Condition	Oncology	Dr. Kailash Mittal	Dr. Siddharth Kumar
5	A phase III, multicenter, randomized, double-blind, parallel-group clinical trial to compare the efficacy and safety of the Cenobamate tablets as adjunctive therapy versus Eslicarbazepine in focal seizures	Neurology	Prof. (Dr.) Ramakant Yadav	Dr. Midhun Mohan
6	A Prospective, multi centre, single arm pivotal study (TAVI), The device consists of Transfemoral delivery catheter and loading system and Transcatheter pericardial aortic valve in size 23, 26 and 29 mm	Cardiology	Dr. Subhash Chandra	Dr. Prachi Jain Rai

All above PIs & Co-PIs are hereby instructed to co-ordinate with Dr. Kamal Pant, Member Secretary IEC.

(Prof. (Dr.) P.K. Jain)
Vice Chancellor

Copy to: For the information and necessary action:

1. All Concerned.
2. Dean (Medical)
3. Finance Officer.
4. Registrar.
5. Member Secretary IRC.
6. Incharge CAC for uploading the order on the website.
7. Personal File.

(Prof. (Dr.) P.K. Jain)
Vice Chancellor

